STOCK TITAN

Citius Oncology grants medical chief 400K stock options

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Citius Oncology, Inc. Chief Medical Officer Myron Czuczman received 400,000 stock options covering 400,000 common shares on November 9, 2026, with an exercise price of $0.5495 per share. The options vest one-third on each of the first, second and third anniversaries, subject to his continuous service to the company or a related entity on each vesting date.

Czuczman also reported direct ownership of 825,000 common shares and existing options covering 400,000 shares at a $1.07 exercise price, expiring December 12, 2034, and 1,400,000 shares at a $2.15 exercise price, expiring July 5, 2033.

Insider Czuczman Myron
Role Chief Medical Officer
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) F1 400,000 $0.00 $0.00
Holding Stock Option (Right to Buy) F2 -- -- --
Holding Stock Option (Right to Buy) F3 -- -- --
Holding Common Stock -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 2,200,000 options, with 1,800,000 underlying shares of Common Stock (Direct); Common Stock — 825,000 shares (Direct)
Footnotes (3)
  1. F1. These options were granted on November 9, 2026. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
  2. F2. These options were granted on December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
  3. F3. These options vest over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
Stock options granted 400,000 options covering 400,000 common shares Granted November 9, 2026; vest one-third on each of the first, second and third anniversaries, subject to continuous service
Exercise price $0.5495 per share New option grant on November 9, 2026
Direct common shares owned 825,000 shares Reported following the November 9, 2026 transaction
Existing options 400,000 underlying common shares at a $1.07 exercise price Expiration date December 12, 2034
Existing options 1,400,000 underlying common shares at a $2.15 exercise price Expiration date July 5, 2033
Stock Option (Right to Buy) financial
"the 400,000-option grant covering common shares"
exercise price financial
"the new option grant’s $0.5495 exercise price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest financial
"the award vests in three installments"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
Continuous Service technical
"vesting is subject to the Reporting Person’s Continuous Service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What option award did CTOR’s chief medical officer receive?

Myron Czuczman, Citius Oncology’s Chief Medical Officer, received 400,000 stock options covering common shares on November 9, 2026, with a $0.5495 exercise price. The options vest in three equal installments on the first, second and third anniversaries, subject to continued service with the company or a related entity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Czuczman Myron

(Last)(First)(Middle)
C/O CITIUS ONCOLOGY, INC.
11 COMMERCE DRIVE, 1ST FLOOR

(Street)
CRANFORD NEW JERSEY 07016

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
CITIUS ONCOLOGY, INC. [ CTOR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock825,000D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$0.549511/09/2026A400,000 (1)11/09/2036Common Stock400,000$0400,000D
Stock Option (Right to Buy)$1.07 (2)12/12/2034Common Stock400,000400,000D
Stock Option (Right to Buy)$2.15 (3)07/05/2033Common Stock1,400,0001,400,000D
Explanation of Responses:
1. These options were granted on November 9, 2026. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
2. These options were granted on December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
3. These options vest over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
/s/ Alexander M. Donaldson, by Power of Attorney11/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading